# Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients

Source: https://onco.cc/trials/nct05558007/  
OnCo record `nct05558007` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tadalafil 5mg in prostate cancer, run by Biozeus Biopharmaceutical S.A., now recruiting.

## Summary

Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients is a phase 2 interventional study registered as NCT05558007 by Biozeus Biopharmaceutical S.A., with 72 participants planned, started 2023-11-22 and due to reach its primary completion in 2024-12-31. Interventions recorded: Tadalafil 5mg, BZ371A, Oral Placebo and Topical Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05558007
- Phase: 2
- Setting: Phase 2 Clinical Trial to Evaluate Safety and Efficacy of BZ371A in a Gel Applied in Patients That Performed Radical Prostatectomy
- Sponsor: Biozeus Biopharmaceutical S.A.
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT05558007: https://clinicaltrials.gov/study/NCT05558007

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct05558007.json